Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Anika Therapeutics, Inc.
  6. News
  7. Summary
    ANIK   US0352551081

ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
22.68 USD   -1.09%
08/04ANIKA THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/03Anika Therapeutics to Seek Acquisitions
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating

11/05/2021 | 12:31pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about ANIKA THERAPEUTICS, INC.
08/04ANIKA THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
08/03Anika Therapeutics to Seek Acquisitions
CI
08/03TRANSCRIPT : Anika Therapeutics, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03ANIKA THERAPEUTICS : Reports Second Quarter Fiscal 2022 Financial Results - Form 8-K
PU
08/03ANIKA : Q2 Earnings Snapshot
AQ
08/03Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q2 Loss $-0.12
MT
08/03Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q2 Revenue $39.7M
MT
08/03Anika Reports Second Quarter Fiscal 2022 Financial Results
AQ
08/03Anika Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -28,9x
Yield 2022 -
Capitalization 331 M 331 M -
Capi. / Sales 2022 2,14x
Capi. / Sales 2023 1,93x
Nbr of Employees 297
Free-Float 98,1%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 22,68 $
Average target price 46,00 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-36.00%330
CSL LIMITED2.07%98 543
SAMSUNG BIOLOGICS CO.,LTD.-0.89%48 860
WUXI BIOLOGICS (CAYMAN) INC.-19.88%40 273
BIOGEN INC.-9.05%31 664
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.97%23 596